Ameriprise Financial Inc. raised its position in shares of United Therapeutics Corp. (NASDAQ:UTHR) by 1.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 115,356 shares of the biotechnology company’s stock after buying an additional 1,995 shares during the period. Ameriprise Financial Inc. owned approximately 0.27% of United Therapeutics Corp. worth $12,218,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in UTHR. Daiwa Securities Group Inc. increased its stake in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock worth $111,000 after buying an additional 150 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 190 shares in the last quarter. Eqis Capital Management Inc. purchased a new stake in shares of United Therapeutics Corp. during the second quarter valued at $254,000. Creative Planning increased its stake in shares of United Therapeutics Corp. by 330.4% in the second quarter. Creative Planning now owns 2,410 shares of the biotechnology company’s stock valued at $255,000 after buying an additional 1,850 shares in the last quarter. Finally, Acrospire Investment Management LLC purchased a new stake in shares of United Therapeutics Corp. during the first quarter valued at $267,000.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 3.98% on Wednesday, reaching $117.15. 532,764 shares of the company’s stock traded hands. The firm has a market capitalization of $5.09 billion, a P/E ratio of 5.66 and a beta of 1.46. The firm’s 50 day moving average is $124.13 and its 200 day moving average is $115.99. United Therapeutics Corp. has a 52 week low of $97.52 and a 52 week high of $164.04.
United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, topping the consensus estimate of $3.22 by $1.33. United Therapeutics Corp. had a return on equity of 49.30% and a net margin of 64.26%. The business had revenue of $412.60 million for the quarter, compared to analyst estimates of $395.15 million. During the same quarter in the previous year, the firm earned $2.55 EPS. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. Analysts expect that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.
UTHR has been the topic of several recent analyst reports. HC Wainwright downgraded shares of United Therapeutics Corp. from a “buy” rating to a “neutral” rating and reduced their target price for the company from $175.00 to $95.00 in a research note on Wednesday, June 15th. Zacks Investment Research raised shares of United Therapeutics Corp. from a “hold” rating to a “strong-buy” rating and set a $125.00 target price on the stock in a research note on Tuesday, July 5th. Wedbush reissued an “outperform” rating and issued a $229.00 target price on shares of United Therapeutics Corp. in a research note on Thursday, July 28th. Jefferies Group reissued a “hold” rating and issued a $120.00 target price on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Finally, JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating on the stock in a research note on Friday, July 29th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. United Therapeutics Corp. currently has an average rating of “Hold” and an average target price of $137.09.
In related news, Director Tommy G. Thompson sold 1,291 shares of the business’s stock in a transaction dated Monday, September 26th. The shares were sold at an average price of $125.57, for a total value of $162,110.87. Following the sale, the director now directly owns 1,291 shares in the company, valued at approximately $162,110.87. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,308 shares of the business’s stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $105.10, for a total transaction of $137,470.80. Following the completion of the sale, the chief executive officer now owns 1,548 shares in the company, valued at $162,694.80. The disclosure for this sale can be found here. Insiders own 7.50% of the company’s stock.
About United Therapeutics Corp.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.